期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三阴性乳腺癌靶向治疗的研究进展 被引量：3

下载PDF
导出
摘要 三阴性乳腺癌(TNBC)是指雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)均为阴性的乳腺癌,具有侵袭性强、转移率高、总生存率低、预后差等临床特点。三阴性乳腺癌还没有标准治疗方案,化疗仍为三阴性乳腺癌的主要治疗方式。目前,三阴性乳腺癌的分子靶向治疗已有大量研究并获得一定的治疗效果,本文就三阴性乳腺癌的靶向治疗现状及进展进行综述。
作者 贺春梅 吴斌
机构地区 西南医科大学附属医院乳腺外科
出处 《西南军医》 2016年第6期558-561,共4页 Journal of Military Surgeon in Southwest China
关键词 乳腺癌 三阴性 靶向治疗
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1CHACON R D, COSTANZO M V. Triple-negative breast cancer EJ]. New England Journal of Medicine, 2010, 363 (20):1938-48.
  • 2PEROU C M, SORLIE T, EISEN M B, et al. Molecular portraits of human breast tumours I J]. Nature, 2000,406 (6797): 747-752.
  • 3王新昭,左文述,刘琪,于志勇.2013年St Gallen乳腺癌会议国际专家共识荟萃[J].中华肿瘤防治杂志,2013,20(23):1859-1864. 被引量：63
  • 4JACOT W, MOLLEVI C, FINA F, et al. High EGFR pro- tein expression and exon 9 PIK3CA, mutations are inde- pendent prognostic factors in triple negative breast cancers IJ]. Bmc Cancer, 2015, 15( 1 ):1-10.
  • 5CAREY LA, RUGO HS, MARCOM PK, et al. TBCRC 001: randomized phase II study of cetuximab in combina- tion with carboplatin in stage IV triple-negative breast can- cer [J]. Journal of Clinical Ontology Official Journal of the American Society of Clinical Oncology, 2012, 30(30): 2615-2623.
  • 6O ' SHAUGHNESSY J, WECKSTEIN D, VUKELJA S. Preliminary results of arandomized phase II study of week- ly irinotecan/carboplatin with orwithout cetuximab in pa- tients with metastatic breast cancerEJ]. Breast Cancer Res Treat, 2007,308 (106): 32-49.
  • 7BING-HE R X. Paclitaxel Plus Bevacizumab Versus Pacli- taxel Alone for Metastatic Breast Cancer EJ]. New Eng- land Journal of Medicine, 2007, 357(26):2666-2676.
  • 8VON M G, EIDTMANN H, REZAI M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. IJ]. New England Journal of Medicine, 2012, 366 (4):299-309.
  • 9O'SHAUGHNESSY J, OSBORNE C, PIPPEN JE. Inipar-ib plus chemotherapy in metastatic Iriple-negative breast cancer. [J]. New England Journal of Medicine, 2011, 364 (3):205-214.
  • 10FINN R S, BENGALA C, IBRAHIM N, et al. Dasatinib as a singleagent in triple-negative breast cancer: results of an open-label phase 2 study IJ]. Clin Cancer Res, 2011,17 (21):6905-6913.

二级参考文献70

  • 1杨清,张淑兰,王玉.子宫内膜癌组织中p-PKB及仅含BH3域蛋白的表达及其相关性[J].中国肿瘤临床,2006,33(16):912-915. 被引量：5
  • 2Goldhirsch A, Wood WC, Coates AS, et al. Strategies for sub types-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011,22 (8):1736 -1747.
  • 3The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours [J]. Nature, 2012, 490 (7418) :61- 70.
  • 4Dunbier AK,Anderson H,Ghazoui Z, et al. Association between breast cancer subtypes and response to neoadjuvant anastrozole [J]. Steroids, 2011,76(8) :736-740.
  • 5Ellis M J, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition[J]. Nature,2012, 486(7403) :353-360.
  • 6Galimberti V,Botteri E,Chifu C,et al. Can we avoid axillary dis- section in the micrometastatic sentinel node in breast cancer? [J]. Breast Cancer Res Treat,2012,131(3) : 819-825.
  • 7Martelli G,Boracchi P,Ardoino I,et al. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial[J]. Ann Surg, 2012,256(6) : 920-924.
  • 8Goldhirsch A,Gelber RD,Piccart-Gebhart MJ,et al. 2 years ver- sus 1 year of adjuvant trastuzumab for HER-2 positive breast cancer (HERA) :an open-label, randomised controlled trial[J]. Lancet,2013,382(9897) :1021-1028.
  • 9Pivot X,Romieu G,Debled M,et al. 6 months versus 12 months of adjuvant trastuzumah for patients with HER-2-positive early breast cancer (PHARE):a randomised phase 3 trial[J]. Lancet Oncol, 2013,14 (8) : 741-748.
  • 10Davies C,Pan H, Godwin J, et al. Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet,2013,381 (9869) :805-816.

共引文献71

同被引文献43

引证文献3

二级引证文献12

西南军医
2016年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部